This test is most useful if any of these apply to you.
Unusual urinary phosphoserine results have been reported in a few rare genetic bone disorders. That makes this a possible supporting clue during a metabolic evaluation, but its accuracy as a standalone diagnostic marker hasn't been established. There is also no demonstrated benefit from using it to guide prevention or longevity decisions in otherwise healthy people.
Serine is an amino acid your body can make for itself. It helps build proteins and the fats in cell membranes and supports nervous system function. Phosphoserine is an intermediate in one of its production pathways. The enzyme phosphoserine phosphatase removes its phosphate group to produce serine.
This test measures free phosphoserine in a spot urine sample through quantitative amino acid analysis. Results are expressed relative to urine creatinine to account for dilution. Creatinine is a waste product produced by muscles and cleared through the kidneys. The urine result describes phosphoserine excretion; it has not been validated as a measure of how quickly your cells make serine or how much serine your brain has available.
Phosphatidylserine is a different substance. It's a fat-based molecule in cell membranes and an ingredient in some supplements. Phosphoserine can also occur within proteins when phosphate groups are attached to their serine units. Measuring those modified proteins is different from measuring free phosphoserine in urine.
This extremely rare genetic condition causes short stature, skeletal changes, and abnormally dense bones. Disease-causing changes in PTDSS1 disrupt the normal control of phosphatidylserine synthase 1. Studies of affected cells show excessive phosphatidylserine production.
One case report described a more than sixfold elevation in urinary phosphoserine in an affected infant, along with excess ethanolamine and smaller increases in serine and phosphoethanolamine. Bone measurements suggested increased bone formation without a corresponding increase in breakdown. The researchers proposed a connection between the urine finding and altered phosphatidylserine production, but the mechanism wasn't established.
That observation hasn't established how consistently urinary phosphoserine rises in this disorder or how well it distinguishes it from other conditions. Diagnosis rests on the clinical and skeletal findings together with genetic testing.
Hypophosphatasia is a genetic disorder involving reduced alkaline phosphatase activity. This enzyme helps bones and teeth mineralize and appears as ALP on routine blood work. The condition can be mild enough to go unrecognized into adulthood.
In a study of one affected family, greater urinary phosphoserine and phosphoethanolamine excretion accompanied lower total and liver ALP activity. There was no comparable relationship with bone-specific ALP. The researchers proposed that altered liver metabolism might contribute to the urine findings; the study did not establish their source or the diagnostic accuracy of urinary phosphoserine.
Phosphoethanolamine is a separate molecule with better evidence as a supporting marker for hypophosphatasia. Its diagnostic performance cannot be assigned to phosphoserine. Modern evaluations rely on persistently low ALP, clinical findings, supporting biochemical tests, and genetic testing when appropriate.
Inherited deficiencies of phosphoserine aminotransferase or phosphoserine phosphatase can impair serine production. The first reported family with aminotransferase deficiency included two siblings with low serine and glycine in blood plasma and cerebrospinal fluid. The older sibling developed severe seizures and developmental problems; the younger sibling was identified before symptoms. The first reported phosphatase-deficiency case was a boy with Williams syndrome who had low serine in those same fluids.
These reports concern serine in blood and the fluid surrounding the brain and spinal cord. They don't establish a diagnostic pattern for urinary phosphoserine. Urine amino acid results are usually uninformative in serine deficiency disorders, so an unremarkable urine profile cannot exclude them.
A study of 1,347 twins and 183 clinic-referred children found an association between higher urinary phosphoserine and aggression in its initial analysis. The association survived adjustment for the many molecules tested, but it did not replicate in comparisons within twin pairs. Phosphoserine was not among the markers taken forward into the final clinical validation analysis.
The researchers discussed vitamin B6 as a possible explanation, but they did not establish urinary phosphoserine as a measure of B6 status or brain serotonin or dopamine. Their results don't support using this measurement to diagnose a vitamin deficiency or explain aggressive behavior.
One study combined eight molecules measured in blood serum, including phosphoserine, in a research model that distinguished small cell lung cancer from other lung cancers and healthy comparison participants. This was a different specimen and a combined model. It does not establish cancer screening or risk prediction from a standalone urinary phosphoserine result.
Phosphoserine is best interpreted alongside these tests.
Phosphoserine is included in these pre-built panels.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.